Table 1 Recent patent applications in polyethylene glycosylation

WO 2012158678

A composition, useful for maintaining polyethylene glycosylation of polypeptides during storage, comprising a polypeptide conjugated to a polyethylene glycol moiety through a maleimide linker.

Bristol-Myers Squibb (Princeton, NJ, USA)

Wang J, Yeung B

5/17/2011

11/22/2012

WO 2012130015

A method of preparing a polyethylene glycol (PEG)ylated exendin analog used for preparing medicaments for treating diabetes mellitus, by reacting a polypeptide raw material with a PEGylation reagent and removing the protection group from the obtained product.

Shanghai Huayi Bio Lab (Shanghai)

Yue P

3/30/2011

10/4/2012

WO 2012053691, KR 2012041980

A new polyethylene glycol (PEG)ylated interferon (IFN)-α isomer used for treating diseases, e.g., cancer, obtained by a modifying amino acid sequence in a specific region of human IFN-α and then binding PEG to the modified amino acid region.

R&D Biolab (Seoul)

Kim YH, Koh CH, Koh D, Koh HK, Song EK, Song GG, Gyu SG, Hyang KY, Hyun KC, Koh H, Kyung SE

10/22/2010

4/26/2012, 5/3/2012

WO 2012031518, CN 102397558

New polyethylene glycosylated exendin-4 analogs used in a composition for preparing medicaments used for preventing and/or treating disease and/or symptoms, e.g., obesity related to glucose metabolism.

Institute of Pharmacology & Toxicology Academy of Military Medical Sciences (Beijing), Chengdu Yiping Medical Science & Technology (Chengdu, China)

Li S, Liang Y, Liu K, Xu X

9/9/2010

3/15/2012, 4/4/2012

CN 102028661

Freeze-dried injection powder of pegylated recombinant human granulocyte colony stimulating factor, comprising, e.g., pegylated recombinant human granulocyte colony-stimulating factor, freeze-dried protective agent and glacial acetic acid.

Shandong New Time Pharmaceutical Co. (Linyi, China)

Liu Z, Zhao Z

12/31/2010

4/27/2011

CN 101947312

A nanoemulsion comprising isopropyl myristate, polyethylene glycol dioctadecanoate, polyglyceryl-3 oleate, pegylated superoxide dismutase solution and cellulose E; has excellent stability, permeability and bioactivity, can be applied directly on skin, and can be produced by a simple method.

Ding K, Dong P

Ding K, Ding Y, Dong P, Yang Y, Zhu X, Zuo X

8/26/2010

1/19/2011

US 20100247508, WO 2010124547

A new polyethylene glycol (PEG)-arginase conjugate comprising a PEG moiety covalently attached to arginase (e.g., human arginase I) at a predetermined position; useful in treating an arginine-dependent disease (e.g., cancer or viral infection).

Leung YC, Lo W, The Hong Kong Polytechnic University (Hong Kong)

Leung YC, Lo W, Lao W, Liang R

3/26/2009

9/30/3010, 11/4/2010

WO 2010048184, US 20100112607

Releasing a reversibly linked water-soluble polymer from a protein modified by the water-soluble polymer by incubating the protein under one or more conditions effective to release the water-soluble polymer.

Baxter Healthcare (Glattpark, Switzerland), Baxter International (Deerfield, IL, USA), Nektar Therapeutics (San Carlos, CA, USA)

Anderle H, Bossard MJ, Culbertson SM, Fang Z, Rottensteiner H, Schrenk G, Turecek P, Varadi K, Weber A, Zappe H, Zhang P

10/21/2008

4/29/2010, 5/6/2010

WO 2010033195

A new conjugate comprising an opioid compound linked to a small water-soluble oligomer via a linker; useful in reducing the addictive properties of an opioid agonist.

Nektar Therapeutics (San Carlos, CA, USA)

Gursahani H, Jude-Fishburn CS, Riley TA, Zacarias AN

9/16/2008

3/25/2010